Showing results (381-390 of 408) with videos related to
Sort By:
Pageof 41
Nature Immunology|February 3, 2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.Biorxiv : the Preprint Server for Biology|September 18, 2025
Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.Biorxiv : the Preprint Server for Biology|January 13, 2025
Transient glycan-shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaquesDaniel J Morris, Jason Gorman, Tongqing Zhou, et al.Science (New York, N.Y.)|June 20, 2015
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersRogier W Sanders, Marit J van Gils, Ronald Derking, et al.Biorxiv : the Preprint Server for Biology|June 21, 2024
HIV-1 neutralizing antibodies in SHIV-infected macaques recapitulate structurally divergent modes of human V2 apex recognition with a single D geneRyan S Roark, Rumi Habib, Jason Gorman, et al.Biorxiv : the Preprint Server for Biology|October 28, 2024
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIVMohammad M Sajadi, Abdolrahim Abbasi, Zahra Rikhtegaran Tehrani, et al.Nature Medicine|October 8, 2021
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trialKathryn E Stephenson, Boris Julg, C Sabrina Tan, et al.Pageof 41